Breaking News

Agere Expands Manufacturing Capabilities

November 6, 2012

Adds cGMP spray drying services

Agere Pharmaceuticals has added cGMP manufacturing capabilities to support clients entering Phase IIb trials. The new capacity extends services for formulation development to oral bioavailability of BCS II and IV compounds.  
 
“We’ve extended our cGMP spray drying capabilities in response to our clients’ requests to continue with Agere as they enter Phase IIb clinical trials,” said Marshall Crew, Agere’s president and chief executive officer. “This is a natural progression for us, as expanding services delivers efficiencies to our clients.”

blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.